Form 4: Aerovate Therapeutics Officer Benjamin T. Dake Reports Stock Transactions

Benjamin T. Dake, an officer at Aerovate Therapeutics, reported the acquisition and disposal of common stock and the exercise of stock options on March 18, 2024, according to a Form 4 filing with the SEC.

Summary

• On March 18, 2024, Benjamin T. Dake, President, Chief Operating Officer, and Secretary of Aerovate Therapeutics, Inc., engaged in multiple transactions involving the company's common stock.
• Dake exercised stock options to acquire 20,557 shares at $2.14 and 14,500 shares at $10.61.
• He then sold 27,476 shares at a weighted average price of $25.7418 and 7,581 shares at a weighted average price of $26.4825.
• These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 16, 2023.
• Following these transactions, Dake directly owns 8,872 shares of common stock and 102,789 stock options exercisable at $2.14 and 43,500 stock options exercisable at $10.61.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it simply reports transactions. The transactions themselves don't necessarily indicate a positive or negative outlook.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. Investors often monitor these filings for insights into management's perspective on the company's stock.

Stakeholder Impact

• The transactions may be of interest to shareholders as they provide insight into the actions of a key officer within the company.

Key Dates